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Abstract 
Childhood immunisation programs have seen well-heralded successes in disease 
control. An increasing number of scheduled vaccines, narrowing risk–benefit ratios, 
and public attention to vaccine safety raise new questions about consent. We first 
explore the challenges that this highly dynamic environment poses for valid consent. 
Then we broaden this discussion to wider public engagement by suggesting how the 
public – the bearers of vaccine risk and benefit – can be better involved in 
immunisation policy.  
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The public health achievements of immunisation are well-recognised, with 
remarkable success in eradication or control of diseases such as smallpox, polio, 
pertussis, measles, mumps, rubella, hepatitis B, tetanus, diphtheria and Haemophilus 
influenzae type b (Hib).1, 2 Further health benefits are expected. Novel technologies 
have enabled development of vaccines against a widening array of diseases including 
human papillomavirus (HPV), and herpes zoster.3 Vaccines against pathogens as 
diverse as human immunodeficiency virus, malaria, tuberculosis, herpes simplex 
virus, dengue fever, Ross River virus, Staphylococcus aureus and Clostridium difficile 
are at varying stages of development.3 Existing programs continue to be updated 
with new combination vaccines, such as measles-mumps-rubella-varicella (MMRV), 
or vaccines for a wider number of disease strains, such as 13-valent pneumococcal 
vaccine, and novel delivery systems are being tested.3  
 
The control of infectious diseases that immunisation has achieved, along with the 
increased number of vaccines offered in childhood schedules, have brought with 
them new challenges for how we communicate the benefits and risks of 
immunisation. This article considers the ethical and policy implications of 
developments in immunisation, for both individual consent and societal involvement 
in decision making, and offers some recommendations for how policy and practices 
can meet these challenges.  
 
1. Individual consent  
In western society, it is broadly accepted in ethics, law and health care that 
individuals should be able to make decisions about their own health care in ways 
that reflect their needs, wishes and values. In health care, the provision of consent is 
the means by which people actualise their autonomy (self-rule or self-
determination), by authorising what happens to them and who touches them.4 For 
consent to be valid, patients (or their parents) must be competent to make the 
decision, sufficiently informed, understand the information provided and be able to 
act freely and voluntarily.5  
 
The contemporary environment in which immunisation programs are administered 
presents a series of challenges to ensuring valid consent. One of these lies in 
managing the volume of information about each vaccine as schedules become 
increasingly ‘crowded’, and a second lies in accommodating different lay and public 
health views about the relative merits of immunisation where the risk–benefit ratios 
of immunisation are less stark and/or less apparent. 
 
Managing the volume of information 
 
There is an increasing number of vaccines recommended for children as part of 
national programs. The Australian National Immunisation Program Schedule 
currently has 6 recommended vaccines against 13 diseases. This compares with 3 
vaccines against 9 diseases prior to 1994. Public and immunisation provider concerns 
about this increase are evident; up to one-third of parents and health professionals 
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feel that children receive too many vaccines6, 7 and there is evidence that parents are 
becoming increasingly selective about whether their child has all vaccines on offer 
and they tend to be more wary of newer vaccines.8, 9  
 
Ensuring valid consent for each new vaccine is increasingly difficult as this requires 
that, for each vaccine, parents must be provided with sufficient information about 
their material risks and benefits. This is particularly the case for parents of children 
aged under 5 years (given the sheer number of recommended vaccines) and for 
parents of medically at-risk and Indigenous children who have more vaccines 
recommended for them. Health professionals must also contend with scientific 
uncertainty about some of the rare but serious diseases associated with vaccination 
where causation is difficult to establish. They must also manage the volume of 
information potentially required and their own sometimes limited knowledge of 
vaccines.10 Given these challenges, it is hardly surprising that studies suggest that in 
practice the ethical and legal standards of consent are often not met.11, 12  
 
Some have suggested that this results from the absence of clear and consistent 
policies and processes for risk communication surrounding immunisation. Health 
professionals and consumers have argued that the absence of sufficient, rigorous 
and consistent information about the relative risks and benefits of immunisation 
undermines public trust in immunisation (as a whole) and undermines the ability of 
individuals to make informed decisions.13 10 This criticism has been most keenly 
expressed when genuine vaccine safety signals arise or when a parent believes they 
were insufficiently warned about a vaccine reaction.14   
 
In response to such concerns and to the medico-legal issues arising from them, in 
some countries, such as the United States, it is mandatory to provide consumers 
with a Vaccine Information Sheet (VIS) at each medical encounter.11 However, as is 
the case with any textual health information, the VIS relies on a standard literacy 
level and cannot replace the patient–provider relationship – which forms the basis of 
discussions about immunisation. Furthermore, even where such information is 
available, many parents will also desire a verbal discussion about risk,15 particularly 
those whose educational or cultural background makes written materials less 
accessible or less appropriate. Other parents – up to half in some surveys -  may 
prefer to leave decisions to the health provider, and may request minimal 
information about immunisation, other than a reassurance that it is ‘beneficial’ and 
‘safe’.16 (BMRB Social Research, Childhood immunisation: Wave 24 report – England 
and minority ethnic respondents, Unpublished report, 2004) 
 
But while there is merit in standardising immunisation information and in providing 
information through different genres, in many ways such strategies misunderstand 
the principles of consent. There is no legal or ethical obligation to provide all 
information about a vaccine – only to provide information that is material (of value 
or importance) to the patient/consumer or parent.5 And this, in the end, only 
becomes clear through interaction between the health provider and patient/parent.  
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Indeed, risk communication in a clinical encounter is more than simply a ‘top-down’ 
supply of information. It is an exchange between a health care provider and 
patient/parent, an ongoing discussion built upon trust and the expectation of care, 
and an ongoing and integral part of the therapeutic relationship.17 This perspective 
acknowledges that both providers and parents have responsibilities. While providers 
need to give information and elicit concerns and questions, parents need to 
communicate their information needs. In this way, providers can identify parents 
with high information needs and pay appropriate attention to a comprehensive risk 
discussion if it is needed.  
 
Morally and clinically robust health communication is difficult and time-consuming 
and ensuring time for this discussion within the constraints of the contemporary 
health care system remains a constant challenge. For this reason, the burden of 
informing patients should be shared by a range of health services, not just the 
individual immunisation provider. Parents should, and often do, have the 
opportunity to receive verbal and written information about immunisation in the 
antenatal period, in maternity units, and from community health services. At the 
point where parents have contact with vaccine providers, such as in GP waiting 
rooms, sufficient materials should be provided prior to a vaccine being given. 
Additional efforts to facilitate valid consent in patients/parents with low levels of 
literacy and/or numeracy, and for those who do not have English as their primary 
language, need to be further developed and made widely available, including 
expansion of interpreter services, interactive internet resources, capacity-
appropriate decision-aids and information sheets in multiple languages.18  
 
Balancing risks and benefits for individuals and communities 
The second challenge for consent relates to narrowing risk-benefit profiles. In the 
developed world, endemic and highly infectious diseases are now largely controlled 
by immunisation; in this environment, new vaccines, while cost-effective as public 
health measures, tend to be for diseases that cause comparatively less mortality and 
morbidity, such as varicella-zoster.   
 
While, for the most part, health professionals can generally assume that parents 
would make decisions to vaccinate their children against diseases such as polio, 
pertussis, diphtheria, tetanus, measles, mumps, rubella and Hib based upon a 
rational assessment that the benefits of immunisation far outweighed the risk, it is 
no longer clear that parents will always make the same decision about newer 
vaccines – where the risk–benefit ratio is lower and/or where infection may be 
neither very prevalent nor lethal. This same rationale may also hold for older 
vaccines when a previously endemic disease such as polio becomes well-controlled 
or is declared eliminated from a region such as is currently the case for polio in the 
Western Pacific region.19, 20  
 
The possibility that existing or newer vaccines might not offer the same balance of 
benefits over risks becomes even more challenging because population-wide 
immunisation programs have benefits that are more than simply the sum of the 
benefits for vaccinated individuals. For mass immunisation programs, building 
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population or ‘herd’ immunity can protect not only those who are immunised, but 
those who are not.21 In other words, those who are directly protected by 
immunisation shield those who have not been vaccinated from getting the disease, 
such as babies too young to have received full protection or those unable to be 
vaccinated for medical reasons. People who exempt their child from immunisation, 
therefore, may still gain benefits from the widespread immunisation of those around 
them without their child facing any of the risks. This is known as the ‘free rider’ 
problem.22  
 
In many ways, of course, the ‘free rider’ behaviour is understandable, because it is 
largely impossible for an individual who decides not to be vaccinated to see the 
nearly imperceptible effect that his or her behaviour has on everyone. The problem 
is, however, that if enough people choose not to be vaccinated, population immunity 
will fall to levels at which outbreaks may occur which will affect those who have not 
been vaccinated, and those who have (since no vaccine offers 100% protection). 
Thus, while a decision not to vaccinate may be rational for the individual who makes 
it, it can lead to harms for whole populations.  
In some countries enforcement of immunisation has helped to manage this problem. 
In Australia high immunisation coverage has been achieved through a range of non-
legislative strategies including provision of free vaccines under the National 
Immunisation Program, financial incentives for immunisation providers and parents, 
tracking of coverage through the Australian Childhood Immunisation Register, school 
exclusion for unvaccinated children during outbreaks, and education.23  
Nevertheless, the question remains of how to ensure valid consent while upholding 
population health. While concern has been expressed (at least at a public policy 
level) that the public benefit of population immunity is sufficiently great that 
communication about the risks of vaccines should be moderated, in fact the limited 
existing literature suggests that (1) the few parents who decline vaccination for their 
children rarely do so out of a conscious decision to free ride - they simply do not 
think vaccines are safe nor effective 24 and (2) parents who lean towards vaccination 
are able to take account of information about both individual and societal risk and 
benefit and, at least for established vaccines, tend to accept the arguments in favour 
of immunisation.22, 25 The problem, however, is that as risk–benefit ratio narrows, it 
becomes easier to understand decisions to refuse immunisation, harder to judge 
such decisions as morally ‘free riding’, and more difficult to sustain arguments in 
favour of mandating such vaccines.26-29 This suggests that clinical decisions about 
immunisation will inevitably turn on decisions that are made about immunisation 
policy and the support of the community for those decisions. In the final section we 
consider why community involvement in, and support for, immunisation policy is 
important, what it requires and how it might be achieved. 
 
2. Community consent and vaccine policy 
The inclusion of vaccines in a national program has traditionally involved the 
deliberations of expert advisory committees who weigh up the benefits of a vaccine 
relative to its costs and make recommendations to government.30 These 
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deliberations typically consider the following: burden of disease, economic 
evaluation, vaccine safety, vaccine effectiveness, feasibility of recommendation, 
recommendations of other countries, feasibility of local vaccine production, and 
public perceptions.31 Recommendations regarding new vaccines may be made with 
varying levels of evidence and scientific certainty, particularly with regards such 
factors as correlates of protection, the extent and length of protection, and the risk 
of rare but serious reactions.  
 
These systems are comprehensive and appropriate but could be further improved by 
more deliberative processes of public engagement. Primarily this is because in every 
situation, irrespective of the strength of evidence, policy decisions will involve trade-
offs and value judgements. For example, there are values at play when deciding 
whether to vaccinate a group where gains are more marginal but still potentially 
important (e.g. rubella and HPV vaccination of boys); in choosing between different 
outcomes (e.g. which outcomes of pertussis should be prioritised in choosing the 
vaccine schedule), and in decisions about which rates of serious side effects are 
acceptable (e.g. the rate of febrile convulsions from influenza vaccination or 
intussusception from rotavirus vaccination). Indeed, contrary to popular belief, as 
‘evidence’ really refers to ‘fact’ plus ‘value’, it is inevitable that value judgements, 
and occasionally political pressure, will come into play in deliberations about 
immunisation policy.32 Furthermore, as governments are empowered to make 
decisions in terms of the public interest it is also inevitable that groups of experts or 
sometimes individuals will be the ones who make judgements about what outcomes 
should be prioritised and what level of risk is acceptable.  
 
Because the harms and benefits of vaccines are borne by the entire community and 
decisions about vaccines are often made under conditions of epidemiological 
uncertainty, in ethical terms a strong case can be made for including the community 
in deliberations about policy and practice. In recent years, this case has been 
increasingly recognised and a range of strategies have been used to achieve it, 
including lay membership of expert panels, community surveys, broad community 
engagement processes, public meetings, citizens’ juries and consensus 
conferences.33-36 
 
Each of these approaches has advantages and disadvantages. Lay membership of 
expert panels is a common approach in immunisation policy development. Here, an 
individual becomes the focal point through which the wider community’s values and 
perspective are channelled. That individual will inevitably have specific interests and 
perspectives and they are usually not sufficiently resourced to gauge, and then 
represent, the views of the entire community. Social research methods, such as 
focus groups, surveys and choice experiments, can provide more representative 
information about likely or actual public responses to policy initiatives, but may 
reflect only uninformed community opinion about matters that are scientifically and 
socially complex. Community consultation through submissions and committees of 
inquiry can collect views from a more informed public, but tend to prejudice the 
views of a vocal minority. While deliberative processes, such as consensus 
conferences and citizens’ juries, may provide inputs into policy decisions that are 
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more informed and more reflective of community values, they also are open to the 
criticism of selection bias and generalisability and are resource intensive.37, 38 Despite 
such drawbacks, however, the development of immunisation policy, particularly in 
areas where the trade-off between public good and personal choice is stark, would 
surely benefit from community participation via processes of deliberative 
democracy.  
 
Finally, listening and valuing the input of citizens will become increasingly important 
as vaccines continue to attain their success and we see a growing focus on vaccine 
safety. For it is in such processes that governments can better understand lay 
perspectives, build mutual trust and engender a more productive conversation that 
works towards the ultimate goal of public health and wellbeing. 
 
Conclusion  
Recent developments in childhood immunisation programs present unique 
challenges – the number of vaccines on offer continue to increase, while at the same 
time the risk–benefit ratios of some vaccines become increasingly narrow. In this 
setting it is increasingly difficult to balance competing demands – public health 
imperatives for high uptake of immunisation, requirements for valid consent, and 
respect for personal choice. But there is no option but to address these challenges as 
consent remains the cornerstone of respect for autonomy in health care and is one 
of the foundations upon which public trust in immunisation is maintained.  
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